m-Trifluoromethyl-diphenyl diselenide, a multi-target selenium compound, prevented mechanical allodynia and depressive-like behavior in a mouse comorbid pain and depression model

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 63, Issue , 2015, Pages 35-46

  Brüning, César Augusto ^a   Martini, Franciele ^a   Soares, Suelen Mendonça ^a   Sampaio, Tuane Bazanella ^a   Gai, Bibiana Mozzaquatro ^a   Duarte, Marta M M F ^b   Nogueira, Cristina Wayne ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^b UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

Author keywords

Depression; Inflammation; Neuropathic pain; P38 MAPK; Selenium

Indexed keywords

3 TRIFLUOROMETHYLDIPHENYL DISELENIDE; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLOOXYGENASE 2; GLUTAMIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; ORGANOSELENIUM DERIVATIVE; SEROTONIN; UNCLASSIFIED DRUG; ANTIDEPRESSANT AGENT; CORTICOSTERONE; CORTICOTROPIN; CYTOKINE; M-TRIFLUOROMETHYL-DIPHENYL DISELENIDE; ORGANOSILICON DERIVATIVE; TRITIUM;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTICLE; CHRONIC DRUG ADMINISTRATION; CHRONIC PAIN; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; ENZYME ACTIVATION; FORCED SWIM TEST; MALE; MOUSE; NOCICEPTION; NONHUMAN; SEROTONIN UPTAKE; TREATMENT OUTCOME; VON FREY TEST; ANIMAL; BLOOD; BRAIN; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; HEMISPHERIC DOMINANCE; HYPERALGESIA; METABOLISM; MOTOR ACTIVITY; NEURALGIA; PATHOLOGY; PERIPHERAL NERVE INJURY; PSYCHOLOGY; SWIMMING; SYNAPTOSOME;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; CORTICOSTERONE; CYTOKINES; DEPRESSION; DISEASE MODELS, ANIMAL; FUNCTIONAL LATERALITY; GLUTAMIC ACID; HYPERALGESIA; MALE; MICE; MOTOR ACTIVITY; NEURALGIA; ORGANOSILICON COMPOUNDS; PERIPHERAL NERVE INJURIES; SEROTONIN; SWIMMING; SYNAPTOSOMES; TRITIUM;

EID: 84930670236     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2015.05.011     Document Type: Article

References (55)

1. Alexander G.M., van Rijn M.A., van Hilten J.J., Perreault M.J., Schwartzman R.J. Changes in cerebrospinal fluid levels of pro-inflammatory cytokines in CRPS. Pain 2005, 116:213-219.
2. Anisman H., Hayley S., Turrin N., Merali Z. Cytokines as a stressor: implications for depressive illness. Int J Neuropsychopharmacol 2002, 5:357-373.
3. Arnow B.A., Hunkeler E.M., Blasey C.M., Lee J., Constantino M.J., Fireman B., et al. Comorbid depression, chronic pain, and disability in primary care. Psychosom Med 2006, 68:262-268.
4. Backonja M.M., Coe C.L., Muller D.A., Schell K. Altered cytokine levels in the blood and cerebrospinal fluid of chronic pain patients. J Neuroimmunol 2008, 195:157-163.
5. Banks W.A. The blood-brain barrier in psychoneuroimmunology. Neurol Clin 2006, 24:413-419.
6. Bluthe R.M., Walter V., Parnet P., Laye S., Lestage J., Verrier D., et al. Lipopolysaccharide induces sickness behavior in rats by a vagal mediated mechanism. C R Acad Sci III-Vie 1994, 317:499-503.
7. Bluthe R.M., Laye S., Michaud B., Combe C., Dantzer R., Parnet P. Role of interleukin-1 beta and tumour necrosis factor-alpha in lipopolysaccharide-induced sickness behaviour: a study with interleukin-1 type I receptor-deficient mice. Eur J Neurosci 2000, 12:4447-4456.
8. Borges V.C., Savegnago L., Dadalt G., Nogueira C.W. Disubstituted diaryl diselenides inhibit [3H]-serotonin uptake in rats. Neurotox Res 2009, 15:57-61.
9. Bravo L., Mico J.A., Rey-Brea R., Perez-Nievas B., Leza J.C., Berrocoso E. Depressive-like states heighten the aversion to painful stimuli in a rat model of comorbid chronic pain and depression. Anesthesiology 2012, 117:613-625.
10. Bruchas M.R., Schindler A.G., Shankar H., Messinger D.I., Miyatake M., Land B.B., et al. Selective p38 alpha MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction. Neuron 2011, 71:498-511.
11. Brüning C.A., Prigol M., Roehrs J.A., Nogueira C.W., Zeni G. Involvement of the serotonergic system in the anxiolytic-like effect caused by m-trifluoromethyl-diphenyl diselenide in mice. Behav Brain Res 2009, 205:511-517.
12. Brüning C.A., Prigol M., Roehrs J.A., Zeni G., Nogueira C.W. Evidence for the involvement of mu-opioid and delta-opioid receptors in the antinociceptive effect caused by oral administration of m-trifluoromethyl-diphenyl diselenide in mice. Behav Pharmacol 2010, 21:621-626.
13. Brüning C.A., Souza A.C., Gai B.M., Zeni G., Nogueira C.W. Antidepressant-like effect of m-trifluoromethyl-diphenyl diselenide in the mouse forced swimming test involves opioid and serotonergic systems. Eur J Pharmacol 2011, 658:145-149.
14. Brüning C.A., Gai B.M., Soares S.M., Martini F., Nogueira C.W. Serotonergic systems are implicated in antinociceptive effect of m-trifluoromethyl diphenyl diselenide in the mouse glutamate test. Pharmacol Biochem Behav 2014, 125:15-20.
15. Busquet P., Nguyen N.K., Schmid E., Tanimoto N., Seeliger M.W., Ben-Yosef T., et al. Ca(v)1.3 L-type Ca2+ channels modulate depression-like behaviour in mice independent of deaf phenotype. Int J Neuropsychopharmacol 2010, 13:499-513.
16. Chiang R.P.Y., Huang C.T., Tsai Y.J. Melatonin reduces median nerve injury-induced mechanical hypersensitivity via inhibition of microglial p38 mitogen-activated protein kinase activation in rat cuneate nucleus. J Pineal Res 2013, 54:232-244.
17. Clark A.K., Yip P.K., Grist J., Gentry C., Staniland A.A., Marchand F., et al. Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proc Natl Acad Sci U S A 2007, 104:10655-10660.
18. Dantzer R. Innate immunity at the forefront of psychoneuroimmunology. Brain Behav Immun 2004, 18:1-6.
19. Dantzer R. Psychoneuroimmunology 2007, 271-280. Elsevier, Amsterdam. R. Ader (Ed.).
20. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006, 59:1116-1127.
21. Farber K., Kettenmann H. Functional role of calcium signals for microglial function. Glia 2006, 54:656-665.
22. Frantz S. Drug discovery: playing dirty. Nature 2005, 437:942-943.
23. Fukuhara K., Ishikawa K., Yasuda S., Kishishita Y., Kim H.K., Kakeda T., et al. Intracerebroventricular 4-methylcatechol (4-MC) ameliorates chronic pain associated with depression-like behavior via induction of brain-derived neurotrophic factor (BDNF). Cell Mol Neurobiol 2012, 32:971-977.
24. Gray E.G., Whittaker V.P. The isolation of nerve endings from brain: an electron-microscopic study of cell fragments derived by homogenization and centrifugation. J Anat 1962, 96:79-88.
25. Hanisch U.K. Microglia as a source and target of cytokines. Glia 2002, 40:140-155.
26. Irwin M.R., Miller A.H. Depressive disorders and immunity: 20years of progress and discovery. Brain Behav Immun 2007, 21:374-383.
27. Ji R.R., Suter M.R. p38 MAPK, microglial signaling, and neuropathic pain. Mol Pain 2007, 3.
28. Joffe R.T., Levitt A.J., Sokolov S.T. Augmentation strategies: focus on anxiolytics. J Clin Psychiatry 1996, 57(Suppl. 7):25-31. [discussion 32-23].
29. Kim C.F., Moalem-Taylor G. Detailed characterization of neuro-immune responses following neuropathic injury in mice. Brain Res 2011, 1405:95-108.
30. Koo J.W., Duman R.S. IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci U S A 2008, 105:751-756.
31. Kroenke K., Bair M.J., Damush T.M., Wu J.W., Hoke S., Sutherland J., et al. Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain a randomized controlled trial. JAMA 2009, 301:2099-2110.
32. Liu H., Kaur J., Dashtipour K., Kinyamu R., Ribak C.E., Friedman L.K. Suppression of hippocampal neurogenesis is associated with developmental stage, number of perinatal seizure episodes, and glucocorticosteroid level. Exp Neurol 2003, 184:196-213.
33. Loftis J.M., Huckans M., Morasco B.J. Neuroimmune mechanisms of cytokine-induced depression: current theories and novel treatment strategies. Neurobiol Dis 2010, 37:519-533.
34. Malynn S., Campos-Torres A., Moynagh P., Haase J. The pro-inflammatory cytokine TNF-alpha regulates the activity and expression of the serotonin transporter (SERT) in astrocytes. Neurochem Res 2013, 38:694-704.
35. Mao J.R., Gold M.S., Backonja M. Combination drug therapy for chronic pain: a call for more clinical studies. J Pain 2011, 12:157-166.
36. Migues P.V., Leal R.B., Mantovani M., Nicolau M., Gabilan N.H. Synaptosomal glutamate release induced by the fraction Bc2 from the venom of the sea anemone Bunodosoma caissarum. Neuroreport 1999, 10:67-70.
37. Millan M.J. Descending control of pain. Prog Neurobiol 2002, 66:355-474.
38. Mitani H., Shirayama Y., Yamada T., Maeda K., Ashby C.R., Kawahara R. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:1155-1158.
39. Murphy D.L., Uhl G.R., Holmes A., Ren-Patterson R., Hall F.S., Sora I., et al. Experimental gene interaction studies with SERT mutant mice as models for human polygenic and epistatic traits and disorders. Genes Brain Behav 2003, 2:350-364.
40. Niederberger E., Geisslinger G. The IKK-NF-kappa B pathway: a source for novel molecular drug targets in pain therapy?. FASEB J 2008, 22:3432-3442.
41. Nogueira C.W., Rocha J.B. Toxicology and pharmacology of selenium: emphasis on synthetic organoselenium compounds. Arch Toxicol 2011, 85:1313-1359.
42. Nogueira C.W., Zeni G., Rocha J.B. Organoselenium and organotellurium compounds: toxicology and pharmacology. Chem Rev 2004, 104:6255-6285.
43. Nutt D.J. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry 2008, 69(Suppl. E1):4-7.
44. Paulmier C. Selenoorganic functional groups. Selenium reagents and intermediates in organic synthesis 1986, 25-51. Pergamon Press, Oxford. 1 ed. C. Paulmier (Ed.).
45. Porsolt R.D., Bertin A., Blavet N., Deniel M., Jalfre M. Immobility induced by forced swimming in rats - effects of agents which modify central catecholamine and serotonin activity. Eur J Pharmacol 1979, 57:201-210.
46. Raison C.L., Miller A.H. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry 2003, 160:1554-1565.
47. Robinson M.J., Edwards S.E., Iyengar S., Bymaster F., Clark M., Katon W. Depression and pain. Front Biosci (Landmark Ed) 2009, 14:5031-5051.
48. Rocha F.F., Lima-Landman M.T., Souccar C., Tanae M.M., De Lima T.C., Lapa A.J. Antidepressant-like effect of Cecropia glazioui Sneth and its constituents - in vivo and in vitro characterization of the underlying mechanism. Phytomedicine 2007, 14:396-402.
49. Rupil L.L., de Bem A.F., Roth G.A. Diphenyl diselenide-modulation of macrophage activation: down-regulation of classical and alternative activation markers. Innate Immun 2012, 18:627-637.
50. Seltzer Z., Dubner R., Shir Y. A novel behavioral-model of neuropathic pain disorders produced in rats by partial sciatic-nerve injury. Pain 1990, 43:205-218.
51. Sluzewska A., Rybakowski J., Bosmans E., Sobieska M., Berghmans R., Maes M., et al. Indicators of immune activation in major depression. Psychiatry Res 1996, 64:161-167.
52. Tsuda M., Mizokoshi A., Shigemoto-Mogami Y., Koizumi S., Inoue K. Activation of p38 mitogen-activated protein kinase in spinal hyperactive microglia contributes to pain hypersensitivity following peripheral nerve injury. Glia 2004, 45:89-95.
53. Von Korff M., Simon G. The relationship between pain and depression. Br J Psychiatry Suppl 1996, 101-108.
54. Walker A.K., Kavelaars A., Heijnen C.J., Dantzer R. Neuroinflammation and comorbidity of pain and depression. Pharmacol Rev 2014, 66:80-101.
55. Zhu C.B., Lindler K.M., Owens A.W., Daws L.C., Blakely R.D., Hewlett W.A. Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters. Neuropsychopharmacology 2010, 35:2510-2520.